News Zentiva S.A.

Equities

End-of-day quote Bucharest S.E. Other stock markets 06:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.46 ^RON	0.00%		+2.98%	+18.49%

Apr. 01	Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	CI
Feb. 29	Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zentiva S A : SCD_Zentiva_Annual Report 2023-EN	Apr. 30	PU
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31	CI
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	Mar. 28	AQ
Zentiva S A : Convening notice Zentiva S.A. – OGMS and EGMS_29.04.2024	Mar. 27	PU
Zentiva S A : Memo_Substantiation note_OGMS_29.04.2024	Mar. 27	PU
Zentiva S A : Draft Resolution_OGMS_29.04.2024	Mar. 27	PU
Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Zentiva S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Zentiva S A : SCD_Zentiva_Fin report 30.06.2023-EN	23-08-31	PU
Zentiva S A : SCD_Zentiva_Fin report 31.03.2023-EN	23-05-15	PU
Zentiva S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
STEFFEN SALTOFTE APPOINTED AS CEO OF ZENTIVA	23-04-19	AQ
Zentiva S A : Memo_Substantiation note_OGMS_27.04.2023	23-03-27	PU
Zentiva S A : Draft Resolution_OGMS_27.04.2023	23-03-27	PU
Zentiva S A : Auditor’s Report_31.12.2022	23-03-27	PU
Zentiva S A : Annual remuneration report for the management of Zentiva SA_2022	23-03-27	PU
Zentiva S A : Remuneration policy for the management of Zentiva_draft	23-03-27	PU
Zentiva S A : Memo_Substantiation note_EGMS_27.04.2023	23-03-27	PU
Zentiva S A : Draft Resolution_EGMS_27.04.2023	23-03-27	PU

No results for this search